Player Avatar grahamfordummies (72.06) Submitted: 12/30/2013 3:54:45 PM : Outperform Start Price: $2.26 DSCO Score: -32.27

Valuation already anticipates slow launch for Surfaxin (infant respiratory distress syndrome or RDS), but is missing the game changer development of Aerosurf (aerosolized inhalation, also for infant RDS, but avoids the intubation required for Surfaxin and all competition). Recent financing extends cash runwat through Surfaxin launch and aerosurf 2b studies in mid 15. Attractive target.

Featured Broker Partners